<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p154" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_154{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_154{left:306px;bottom:30px;}
#t3_154{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_154{left:346px;bottom:30px;}
#t5_154{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_154{left:517px;bottom:30px;}
#t7_154{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_154{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_154{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_154{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_154{left:35px;bottom:777px;letter-spacing:0.11px;word-spacing:0.08px;}
#tc_154{left:35px;bottom:754px;}
#td_154{left:42px;bottom:754px;letter-spacing:0.1px;}
#te_154{left:293px;bottom:754px;letter-spacing:0.17px;word-spacing:0.02px;}
#tf_154{left:35px;bottom:731px;letter-spacing:0.12px;word-spacing:0.06px;}
#tg_154{left:35px;bottom:707px;letter-spacing:0.19px;}
#th_154{left:540px;bottom:715px;letter-spacing:0.1px;}
#ti_154{left:35px;bottom:667px;letter-spacing:0.17px;word-spacing:0.01px;}
#tj_154{left:35px;bottom:645px;letter-spacing:0.09px;word-spacing:0.09px;}
#tk_154{left:35px;bottom:622px;letter-spacing:0.11px;word-spacing:0.08px;}
#tl_154{left:35px;bottom:599px;letter-spacing:0.05px;word-spacing:-0.48px;}
#tm_154{left:35px;bottom:575px;letter-spacing:0.09px;word-spacing:0.09px;}
#tn_154{left:35px;bottom:552px;letter-spacing:0.06px;word-spacing:0.12px;}
#to_154{left:35px;bottom:529px;letter-spacing:0.14px;word-spacing:-0.18px;}
#tp_154{left:35px;bottom:506px;letter-spacing:0.15px;word-spacing:0.04px;}
#tq_154{left:35px;bottom:482px;letter-spacing:0.13px;word-spacing:0.06px;}
#tr_154{left:35px;bottom:442px;letter-spacing:0.07px;word-spacing:-0.99px;}
#ts_154{left:35px;bottom:419px;letter-spacing:0.51px;}
#tt_154{left:109px;bottom:426px;letter-spacing:0.1px;}
#tu_154{left:149px;bottom:419px;letter-spacing:0.07px;word-spacing:0.12px;}
#tv_154{left:35px;bottom:396px;letter-spacing:0.06px;word-spacing:0.12px;}
#tw_154{left:35px;bottom:372px;letter-spacing:0.18px;word-spacing:0.01px;}
#tx_154{left:35px;bottom:349px;letter-spacing:0.08px;word-spacing:0.11px;}
#ty_154{left:35px;bottom:326px;letter-spacing:0.14px;word-spacing:-0.8px;}
#tz_154{left:35px;bottom:303px;letter-spacing:0.14px;word-spacing:-0.4px;}
#t10_154{left:35px;bottom:280px;letter-spacing:0.19px;}
#t11_154{left:161px;bottom:287px;letter-spacing:-0.01px;}
#t12_154{left:35px;bottom:241px;letter-spacing:-0.15px;word-spacing:0.57px;}
#t13_154{left:35px;bottom:217px;letter-spacing:0.14px;word-spacing:-0.58px;}
#t14_154{left:35px;bottom:194px;letter-spacing:0.14px;word-spacing:0.04px;}
#t15_154{left:35px;bottom:171px;letter-spacing:0.07px;word-spacing:0.11px;}
#t16_154{left:35px;bottom:148px;letter-spacing:0.14px;word-spacing:0.05px;}
#t17_154{left:391px;bottom:148px;letter-spacing:0.12px;word-spacing:0.06px;}
#t18_154{left:35px;bottom:124px;letter-spacing:0.28px;}
#t19_154{left:130px;bottom:124px;letter-spacing:0.07px;word-spacing:-0.36px;}
#t1a_154{left:35px;bottom:101px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1b_154{left:141px;bottom:101px;letter-spacing:0.19px;}
#t1c_154{left:387px;bottom:101px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1d_154{left:35px;bottom:78px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1e_154{left:35px;bottom:55px;letter-spacing:0.07px;word-spacing:-0.19px;}
#t1f_154{left:618px;bottom:777px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1g_154{left:618px;bottom:754px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1h_154{left:618px;bottom:731px;letter-spacing:0.02px;word-spacing:0.03px;}
#t1i_154{left:618px;bottom:707px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1j_154{left:618px;bottom:684px;letter-spacing:0.12px;}
#t1k_154{left:618px;bottom:645px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1l_154{left:618px;bottom:622px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1m_154{left:618px;bottom:599px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1n_154{left:1094px;bottom:606px;}
#t1o_154{left:1139px;bottom:599px;letter-spacing:0.44px;}
#t1p_154{left:618px;bottom:575px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1q_154{left:618px;bottom:552px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1r_154{left:618px;bottom:529px;letter-spacing:0.09px;word-spacing:-0.21px;}
#t1s_154{left:618px;bottom:506px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1t_154{left:618px;bottom:482px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1u_154{left:618px;bottom:459px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t1v_154{left:618px;bottom:436px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t1w_154{left:618px;bottom:413px;letter-spacing:0.12px;word-spacing:-1.01px;}
#t1x_154{left:1052px;bottom:420px;letter-spacing:-0.31px;}
#t1y_154{left:1095px;bottom:413px;letter-spacing:-0.09px;word-spacing:0.28px;}
#t1z_154{left:618px;bottom:390px;letter-spacing:0.19px;word-spacing:0.01px;}
#t20_154{left:618px;bottom:366px;letter-spacing:0.07px;word-spacing:0.12px;}
#t21_154{left:618px;bottom:343px;letter-spacing:0.1px;word-spacing:-0.74px;}
#t22_154{left:618px;bottom:320px;letter-spacing:0.13px;word-spacing:-1.17px;}
#t23_154{left:957px;bottom:327px;letter-spacing:0.1px;}
#t24_154{left:1001px;bottom:320px;letter-spacing:0.01px;word-spacing:-1.07px;}
#t25_154{left:618px;bottom:297px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t26_154{left:618px;bottom:273px;letter-spacing:0.17px;word-spacing:0.02px;}
#t27_154{left:618px;bottom:250px;letter-spacing:0.15px;word-spacing:0.03px;}
#t28_154{left:618px;bottom:227px;letter-spacing:0.17px;word-spacing:-1px;}
#t29_154{left:618px;bottom:204px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2a_154{left:618px;bottom:181px;letter-spacing:0.33px;word-spacing:-0.14px;}
#t2b_154{left:749px;bottom:188px;letter-spacing:0.1px;}
#t2c_154{left:794px;bottom:181px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2d_154{left:618px;bottom:157px;letter-spacing:0.24px;word-spacing:-0.05px;}
#t2e_154{left:618px;bottom:134px;letter-spacing:0.13px;word-spacing:-1.18px;}
#t2f_154{left:618px;bottom:111px;letter-spacing:0.16px;word-spacing:-0.86px;}
#t2g_154{left:925px;bottom:118px;}
#t2h_154{left:969px;bottom:111px;letter-spacing:-0.07px;word-spacing:-0.99px;}
#t2i_154{left:618px;bottom:88px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2j_154{left:618px;bottom:64px;letter-spacing:0.16px;word-spacing:0.02px;}
#t2k_154{left:1139px;bottom:72px;letter-spacing:-0.01px;}
#t2l_154{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_154{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_154{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_154{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_154{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_154{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_154{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_154{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_154{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_154{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s9_154{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts154" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg154Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg154" style="-webkit-user-select: none;"><object width="1210" height="935" data="154/154.svg" type="image/svg+xml" id="pdf154" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_154" class="t s0_154">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_154" class="t s1_154">© </span>
<span id="t3_154" class="t s0_154">(NCCN </span>
<span id="t4_154" class="t s1_154">© </span>
<span id="t5_154" class="t s0_154">), All rights reserved. NCCN Guidelines </span>
<span id="t6_154" class="t s1_154">® </span>
<span id="t7_154" class="t s0_154">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_154" class="t s2_154">NCCN Guidelines Version 4.2024 </span>
<span id="t9_154" class="t s2_154">Head and Neck Cancers </span>
<span id="ta_154" class="t s3_154">MS-13 </span>
<span id="tb_154" class="t s4_154">College of Radiology describe basic technical specifications </span>
<span id="tc_154" class="t s4_154">(</span><span id="td_154" class="t s5_154">http://www.acr.org/Quality-Safety</span><span id="te_154" class="t s4_154">). Furthermore, major consensus </span>
<span id="tf_154" class="t s4_154">contouring guidelines for treatment of H&amp;N cancers are available for </span>
<span id="tg_154" class="t s4_154">reference, especially for patients who are treated without surgery. </span>
<span id="th_154" class="t s6_154">143,144 </span>
<span id="ti_154" class="t s4_154">When radiation is given with definitive intent, the dosages prescribed for </span>
<span id="tj_154" class="t s4_154">gross disease are fairly standard, usually in the range of 70 Gy (at </span>
<span id="tk_154" class="t s4_154">approximately 2 Gy/fraction/day) for the following sites: lip, oral cavity, </span>
<span id="tl_154" class="t s4_154">nasopharynx, oropharynx, hypopharynx, glottic larynx, supraglottic larynx, </span>
<span id="tm_154" class="t s4_154">occult primary, salivary gland tumors, and MM. A second dose (often </span>
<span id="tn_154" class="t s4_154">approximately 60 Gy, but varies) may be used to cover volumes </span>
<span id="to_154" class="t s4_154">considered at the highest risk for microscopic spread, while a lower dose </span>
<span id="tp_154" class="t s4_154">(often approximately 50 Gy, but varies) is used for volumes treated </span>
<span id="tq_154" class="t s4_154">electively with low risk for microscopic spread. </span>
<span id="tr_154" class="t s4_154">Although several palliative RT regimens are provided, no single regimen is </span>
<span id="ts_154" class="t s4_154">preferred </span>
<span id="tt_154" class="t s6_154">145,146 </span>
<span id="tu_154" class="t s4_154">; specific regimens vary widely among NCCN Member </span>
<span id="tv_154" class="t s4_154">Institutions. Any palliative RT regimen that might cause severe toxicities </span>
<span id="tw_154" class="t s4_154">should be avoided. More hypofractionated regimens may be useful for </span>
<span id="tx_154" class="t s4_154">patients with limited life expectancy, such as a few months. For example, </span>
<span id="ty_154" class="t s4_154">a common version of the QUAD SHOT regimen consists of a dose of 44.4 </span>
<span id="tz_154" class="t s4_154">Gy, delivered in 12 fractions over three cycles, with each cycle separated </span>
<span id="t10_154" class="t s4_154">by 2 to 3 weeks. </span>
<span id="t11_154" class="t s6_154">147 </span>
<span id="t12_154" class="t s7_154">Radiation Doses </span>
<span id="t13_154" class="t s4_154">Selection of an exact radiation dose prescription and schedule of delivery </span>
<span id="t14_154" class="t s4_154">depends on the primary tumor and neck node size, whether altered </span>
<span id="t15_154" class="t s4_154">fractionation is used, and clinical circumstances, including whether </span>
<span id="t16_154" class="t s4_154">concurrent systemic therapy will be used (see </span><span id="t17_154" class="t s8_154">Principles of Radiation </span>
<span id="t18_154" class="t s8_154">Techniques </span><span id="t19_154" class="t s4_154">in the NCCN Guidelines for Head and Neck Cancers and see </span>
<span id="t1a_154" class="t s4_154">the individual </span><span id="t1b_154" class="t s8_154">Principles of Radiation Therapy </span><span id="t1c_154" class="t s4_154">for each primary site). The </span>
<span id="t1d_154" class="t s4_154">dose may need to be decreased if it is prescribed very close to adjacent </span>
<span id="t1e_154" class="t s4_154">organ at risk (eg, brain, cochlea, optic chiasm and nerves, spinal cord). In </span>
<span id="t1f_154" class="t s4_154">these cases, precise target definition and delineation is crucial, and on- </span>
<span id="t1g_154" class="t s4_154">treatment imaging should be used to ensure accurate radiation delivery. </span>
<span id="t1h_154" class="t s4_154">Anatomical changes (eg, rapidly shrinking tumors, changes in air cavities, </span>
<span id="t1i_154" class="t s4_154">significant weight loss) may necessitate repeat imaging and treatment </span>
<span id="t1j_154" class="t s4_154">replanning. </span>
<span id="t1k_154" class="t s4_154">When treating definitively using conventional fractionation, the primary </span>
<span id="t1l_154" class="t s4_154">tumor and involved lymph nodes (ie, high-risk sites) generally require a </span>
<span id="t1m_154" class="t s4_154">total of 66 Gy (2.0–2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction). </span>
<span id="t1n_154" class="t s6_154">148-151 </span>
<span id="t1o_154" class="t s4_154">For </span>
<span id="t1p_154" class="t s4_154">areas considered highly sensitive to radiation, such as neural structures, </span>
<span id="t1q_154" class="t s4_154">some clinicians feel that the fractionation should be slightly modified (eg, </span>
<span id="t1r_154" class="t s4_154">&lt;2.0 Gy/fraction for at least some of the treatment) to minimize toxicity; in </span>
<span id="t1s_154" class="t s4_154">these cases, additional fractions can be added depending on clinical </span>
<span id="t1t_154" class="t s4_154">circumstances to increase the total physical dose. For instance, a </span>
<span id="t1u_154" class="t s4_154">hyperfractionated schedule allows gross disease to be prescribed a dose </span>
<span id="t1v_154" class="t s4_154">up to 81.6 Gy (at 1.2 Gy/fraction); hyperfractionation has been used for </span>
<span id="t1w_154" class="t s4_154">situations when tumor is abutting brain or optic structures. </span>
<span id="t1x_154" class="t s6_154">148,149 </span>
<span id="t1y_154" class="t s4_154">Care must </span>
<span id="t1z_154" class="t s4_154">be taken if prescribed doses exceed 72 Gy using conventional </span>
<span id="t20_154" class="t s4_154">fractionation (2.0 Gy/fraction), as this may lead to unacceptable rates of </span>
<span id="t21_154" class="t s4_154">normal tissue injury; however, these data were collected in the era prior to </span>
<span id="t22_154" class="t s4_154">advanced techniques such as IMRT or IMPT. </span>
<span id="t23_154" class="t s6_154">148,152 </span>
<span id="t24_154" class="t s4_154">In contrast, when using </span>
<span id="t25_154" class="t s4_154">conventional fractionation, elective irradiation to low- and intermediate-risk </span>
<span id="t26_154" class="t s4_154">sites is usually prescribed at 44 Gy (2.0 Gy/fraction) to 63 Gy (1.6–1.8 </span>
<span id="t27_154" class="t s4_154">Gy/fraction), depending on the estimated risk of tumor involvement, and </span>
<span id="t28_154" class="t s4_154">on whether 3D conformal RT (3D-CRT) or IMRT is used. For 3D-CRT and </span>
<span id="t29_154" class="t s4_154">sequential plans using IMRT, a range of 44–50 Gy (2.0 Gy/fraction) is </span>
<span id="t2a_154" class="t s4_154">often suggested. </span>
<span id="t2b_154" class="t s6_154">153,154 </span>
<span id="t2c_154" class="t s4_154">For simultaneous integrated boost (SIB) IMRT, a </span>
<span id="t2d_154" class="t s4_154">range of doses from 54–63 Gy (1.6–1.8 Gy/fraction) can be used </span>
<span id="t2e_154" class="t s4_154">depending on the fractionation schedule and the risk of tumor involvement </span>
<span id="t2f_154" class="t s4_154">in the area where the dose is prescribed. </span>
<span id="t2g_154" class="t s6_154">154-156 </span>
<span id="t2h_154" class="t s4_154">In definitive RT, the delivery </span>
<span id="t2i_154" class="t s4_154">of six fractions per week is widely accepted, in a mildly accelerated </span>
<span id="t2j_154" class="t s4_154">schedule, especially if chemotherapy is not prescribed concurrently. </span>
<span id="t2k_154" class="t s6_154">150 </span>
<span id="t2l_154" class="t s9_154">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
